Application of dimethyldiguanide as active component in medicine for treating disc degeneration disease

Abstract

The invention discloses an application of dimethyldiguanide as an active component in a medicine for treating a disc degeneration disease. The application of the dimethyldiguanide to a product for treating and delaying the animal disc degeneration disease is a medical new application of the dimethyldiguanide as a medicine, which indicates that the dimethyldiguanide has a good effect for treating the disc degeneration disease.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to the application of metformin as an active ingredient in a drug for treating degenerative disc disease. Background technique [0002] Metformin is currently one of the most widely used oral hypoglycemic agents in the world, and has been used in clinical practice for more than 50 years. Metformin has good monotherapy / combination therapy efficacy and safety evidence, and good health economics benefit evidence. Whether it is for blood sugar control or the prevention of cardiovascular complications of diabetes, it has clear clinical evidence. Therefore, the drug has become the core drug for controlling diabetes in the world. In my country, metformin has been used for nearly 20 years. In 1995, the FDA officially approved metformin for the treatment of type II diabetes (T2DM), and in 2004 the European Union officially approved metformin for the treatment of T2DM in children over 10 years...

AI Technical Summary

Problems solved by technology

[0003] At present, the medical use of metformin is mainly concentrated on type II diabetes. Although it has also bee

Images